Challenges and opportunities: CAR-T cell therapy in autoimmune diseases

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy is expanding from cancer to autoimmune disorders.
• B cell-mediated diseases like lupus, scleroderma, and myopathies are key targets.
• Immune cell depletion via CAR-T therapy can induce remission in refractory patients.

Purpose of the Study:

• To review obstacles and opportunities for CAR-T cell therapy in autoimmune diseases.
• To highlight clinical studies, novel targets, and engineering strategies.
• To discuss allogeneic CAR-T platforms for autoimmune conditions.

Main Methods:

• Review of current literature and clinical studies on CAR-T therapy in autoimmune diseases.
• Analysis of challenges including target selection, safety (cytokine release syndrome, infection), and manufacturing.
• Evaluation of autologous and allogeneic CAR-T approaches.

Main Results:

• Deep immune cell depletion can lead to drug-free remission in autoimmune patients.
• Significant challenges exist in translating CAR-T therapy from oncology to autoimmune settings.
• Beyond CD19, other targets and engineering strategies are being explored.

Conclusions:

• CAR-T cell therapy holds potential for treating severe autoimmune diseases.
• Overcoming challenges in target selection, safety, and manufacturing is crucial for clinical translation.
• Allogeneic CAR-T platforms offer potential for scalability but have limitations.